Innomar’s commitment to drug safety standards

Transcript of 'Innomar’s commitment to drug safety standards '

How does Innomar’s drug safety team provide support for manufacturers in a patient support program landscape? 

Working with Innomar's Drug Safety team offers a multitude of benefits: 

With decades of experience, Innomar expertly manages and submits safety information, aligning with Canadian regulatory standards to mitigate compliance risks.  

Each case undergoes thorough review, logic analysis, and quality control checks to prevent over-reporting, reduce administrative burdens, and maintain accuracy, demonstrating rigorous verification and quality control practices.  

Innomar exercises continuous oversight, and is always prepared for regulatory inspections, client audits, and internal reviews, ensuring seamless adherence to drug safety requirements, illustrating a strong commitment to compliance and audit readiness.  

Innomar drug safety aligns safety reporting with manufacturers' expectations, offering strategic insights to optimize pharmacovigilance operations, expanding services beyond just case report submissions.  

At Innomar, drug safety is a responsibility, not just a function, demonstrating our commitment to patient safety, manufacturer support, and compliance in every managed case report.

The information provided in this piece does not constitute legal or medical advice. Innomar Strategies Inc. and its parent Cencora, Inc. strongly encourage the audience to review available information related to the topics discussed to rely on their own experience and expertise in making decisions related thereto. Further, the contents of this piece are owned by Innomar Strategies, and reproduction is not permitted without the consent of Innomar Strategies.